Get the Stockscreener App
1.68
1.20%
0.02
After Hours:
1.68
Aldeyra Therapeutics Inc stock is traded at $1.68, with a volume of 1.31M.
It is up +1.20% in the last 24 hours and down -8.20% over the past month.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
See More
Previous Close:
$1.66
Open:
$1.63
24h Volume:
1.31M
Relative Volume:
0.45
Market Cap:
$101.34M
Revenue:
-
Net Income/Loss:
$-33.85M
P/E Ratio:
-2.9798
EPS:
-0.5638
Net Cash Flow:
$-33.35M
1W Performance:
-2.89%
1M Performance:
-8.20%
6M Performance:
-66.73%
1Y Performance:
-22.22%
1-Day Range:
$1.60
$1.705
1-Week Range:
$1.60
$1.805
52-Week Range:
$1.07
$6.175
Aldeyra Therapeutics Inc Stock (ALDX) Company Profile
Name
Aldeyra Therapeutics Inc
Sector
Industry
Phone
781-761-4904
Address
131 HARTWELL AVENUE, LEXINGTON, MA
Compare ALDX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALDX
Aldeyra Therapeutics Inc
|
1.68 | 100.13M | 0 | -33.85M | -33.35M | -0.5638 |
VRTX
Vertex Pharmaceuticals Inc
|
436.95 | 114.32B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
698.25 | 74.74B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
799.32 | 51.13B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
286.98 | 39.18B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
145.66 | 31.78B | 742.00K | -1.37B | -1.07B | -7.0731 |
Aldeyra Therapeutics Inc Stock (ALDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-18-26 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Apr-03-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Apr-02-24 | Resumed | H.C. Wainwright | Buy |
| Apr-27-22 | Resumed | H.C. Wainwright | Buy |
| Feb-08-21 | Initiated | H.C. Wainwright | Buy |
| Dec-16-20 | Initiated | Berenberg | Buy |
| Oct-30-20 | Initiated | Jefferies | Buy |
| Oct-16-20 | Initiated | BTIG Research | Buy |
| Sep-22-20 | Initiated | Alliance Global Partners | Buy |
| May-12-20 | Initiated | Oppenheimer | Outperform |
| Dec-04-18 | Initiated | Citigroup | Buy |
| Sep-26-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Sep-13-18 | Initiated | Janney | Buy |
| Jan-26-18 | Initiated | Seaport Global Securities | Buy |
| Sep-26-16 | Initiated | H.C. Wainwright | Buy |
| Jul-01-16 | Initiated | Stifel | Buy |
| Jul-01-15 | Initiated | Canaccord Genuity | Buy |
| Mar-25-15 | Initiated | Chardan Capital Markets | Buy |
| Mar-20-15 | Reiterated | H.C. Wainwright | Buy |
| Nov-18-14 | Initiated | H.C. Wainwright | Buy |
| Jun-19-14 | Initiated | Aegis Capital | Buy |
View All
Aldeyra Therapeutics Inc Stock (ALDX) Latest News
ALDX STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aldeyra Therapeutics, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Perceptive (ALDX) amendment shows 0% ownership; Joseph Edelman signs - Stock Titan
ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
ALDX Deadline Alert: The Gross Law Firm Reminds Aldeyra Therapeutics, Inc. (ALDX) Investors of Securities Class Action Deadline on May 29, 2026 - The Daily Tribune News
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aldeyra Therapeutics, Inc. Of Class Action Lawsuit and Upcoming DeadlinesALDX - ChartMill
ALDX SEC FilingsAldeyra Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
ALDX INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Aldeyra Therapeutics (ALDX) Investors of Securities Class Action Deadline on May 29, 2026 - ChartMill
Bronstein, Gewirtz & Grossman LLC Urges Aldeyra Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire Inc.
ALDX Investor Alert: Aldeyra Therapeutics Securities Fraud LawsuitInvestors With Losses May Seek to Lead the Class Action After Executive Allegedly Approved Misleading Disclosures: Levi & Korsinsky - PR Newswire
ALDX Stockholders Have Opportunity to Lead Aldeyra Therapeutics - The National Law Review
ALDX DEADLINE NOTICE: Aldeyra Therapeutics, Inc. Investors Encouraged to Contact Kirby McInerney LLP By May 29, 2026 - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aldeyra Therapeutics, Inc. Of Class Action Lawsuit and Upcoming Deadlines – ALDX - ChartMill
ALDX DEADLINE: The Gross Law Firm Reminds Aldeyra Therapeutics, - GuruFocus
ALDX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds - The National Law Review
ROSEN, THE FIRST FILING FIRM, Encourages Aldeyra - GlobeNewswire
Portnoy Law Firm Announces Class Action on Behalf of Aldeyra Therapeutics, Inc. Investors - GlobeNewswire
ALDX DEADLINE: The Gross Law Firm Reminds Aldeyra Therapeutics, Inc. Investors of Upcoming Securities Class Action Deadline - PR Newswire
Bragar Eagel & Squire, P.C. Encourages Aldeyra Therapeutics, Inc. Investors with Large Losses to Contact the Firm Regarding Their Rights Before May 29th - GlobeNewswire
symbol__ Stock Quote Price and Forecast - CNN
ALDX Investor Alert: Aldeyra Therapeutics Securities Fraud - GlobeNewswire
MSN Money - MSN
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the FirmALDX - TMX Newsfile
H.C. Wainwright Maintains Aldeyra Therapeutics(ALDX.US) With Hold Rating, Maintains Target Price $2 - Moomoo
ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm - ChartMill
Bronstein, Gewirtz & Grossman LLC Urges Aldeyra Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - mydailyrecord.com
ALDX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aldeyra Therapeutics, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Aldeyra Therapeutics, Inc. Investors to ... - Black Hills Pioneer
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - GlobeNewswire Inc.
ROSEN, LEADING INVESTOR COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by The FirmALDX - ACCESS Newswire
Aldeyra Therapeutics Inc expected to post a loss of 13 cents a shareEarnings Preview - TradingView
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the FirmALDX - TMX Newsfile
ALDX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aldeyra Therapeutics, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit ... - Herald and News
ALDX DEADLINE: The Gross Law Firm Reminds Aldeyra - GlobeNewswire
Number of shareholders of Aldeyra Therapeutics, Inc. – NASDAQ:ALDX - TradingView
ALDX INVESTOR ALERT: Contact Kirby McInerney LLP About Securities Class Action Lawsuit On Behalf of Aldeyra Therapeutics, Inc. Investors - ACCESS Newswire
[10-Q] Aldeyra Therapeutics, Inc. Quarterly Earnings Report - Stock Titan
ALDX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aldeyra Therapeutics, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Aldeyra Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Bronstein, Gewirtz & Grossman LLC Urges Aldeyra - GlobeNewswire
ALDX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aldeyra Therapeutics, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Press releases provided by CNW - Techaeris
ROSEN, A TOP RANKED LAW FIRM, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the FirmALDX - TMX Newsfile
Biotech Downgraded to Neutral After Second FDA CRL for Reproxalap in Dry Eye Disease - Streetwise Reports
ALDX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
ALDX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aldeyra Therapeutics, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
ALDX UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Aldeyra Therapeutics (ALDX) Investors of Securities Class Action Deadline on May 29, 2026 - ChartMill
ALDX UPCOMING DEADLINE : The Gross Law Firm Alerts Aldeyra Therapeutics, Inc. Stockholders of Securities Class ActionContact the Firm - Morningstar
Pleasing Signs As A Number Of Insiders Buy Aldeyra Therapeutics Stock - Yahoo Finance
ROSEN, LEADING INVESTOR COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the FirmALDX - TMX Newsfile
ALDX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aldeyra Therapeutics, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Aldeyra Therapeutics Inc Stock (ALDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Aldeyra Therapeutics Inc Stock (ALDX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Alfieri Michael | Principal Financial Officer |
Mar 18 '26 |
Buy |
1.42 |
5,000 |
7,100 |
7,500 |
| Alfieri Michael | Principal Financial Officer |
Aug 13 '25 |
Buy |
5.30 |
2,500 |
13,250 |
2,500 |
| Machatha Stephen | Chief Development Officer |
Aug 11 '25 |
Sale |
5.15 |
22,073 |
113,713 |
221,799 |
0.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):